keyword
MENU ▼
Read by QxMD icon Read
search

Plaque psoriasis

keyword
https://www.readbyqxmd.com/read/28214309/wirksamkeit-und-sicherheit-von-fumars%C3%A3-ureestern-in-kombination-mit-phototherapie-bei-patienten-mit-moderater-bis-schwerer-plaque-psoriasis-fast
#1
Peter Weisenseel, Kristian Reich, Wiebke Griemberg, Katharina Merten, Christine Gröschel, Natalie Nunez Gomez, Kirsi Taipale, Beate Bräu, Ina Zschocke
HINTERGRUND: Die Behandlung von Psoriasis-Patienten mit einer Kombination aus Fumarsäureestern (FSE, Fumaderm(®) ) und Phototherapie (UV) ist verbreitet, wurde aber im Rahmen von Studien wenig untersucht. Bisher liegen lediglich Daten aus einer kleinen Pilotstudie vor. Intention dieser Studie war, eine FSE/UV-Kombinationsbehandlung an einem größeren Patientenkollektiv mit mittelschwerer bis schwerer Psoriasis zu untersuchen. PATIENTEN UND METHODIK: In dieser prospektiven, multizentrischen, nichtinterventionellen Studie wurden Daten von Patienten mit FSE/UV-Kombinationstherapie hinsichtlich der Wirksamkeit (PGA' PASI, DLQI, EQ-5D), Sicherheit und Dosierung über einen Zeitraum von zwölf Monaten erfasst und mit Daten einer retrospektiven Studie mit FSE-Monotherapie verglichen...
February 2017: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/28214304/efficacy-and-safety-of-fumaric-acid-esters-in-combination-with-phototherapy-in-patients-with-moderate-to-severe-plaque-psoriasis-fast
#2
Peter Weisenseel, Kristian Reich, Wiebke Griemberg, Katharina Merten, Christine Gröschel, Natalie Nunez Gomez, Kirsi Taipale, Beate Bräu, Ina Zschocke
BACKGROUND: While treatment of patients with moderate-to-severe psoriasis using a combination of fumaric acid esters (FAE, Fumaderm(®) ) and phototherapy (UV) is common practice, there have been hardly any studies investigating this regimen. Available information is limited to data from a small pilot study. The objective of the present study was to evaluate FAE/UV combination therapy in a larger patient cohort with moderate-to-severe psoriasis. PATIENTS AND METHODS: In this prospective noninterventional multicenter study, data from patients treated with FAE/UV combination therapy was assessed with regard to efficacy (PGA' PASI, DLQI, EQ-5D), safety, and dosage over a twelve-month period...
February 2017: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/28213862/apremilast-a-review-in-psoriasis-and-psoriatic-arthritis
#3
Gillian M Keating
Apremilast (Otezla(®)) is an orally administered, small molecule inhibitor of phosphodiesterase 4 (PDE4). Apremilast 30 mg twice daily reduced the severity of moderate to severe plaque psoriasis in the phase 3 ESTEEM trials, as well as improving difficult-to-treat nail, scalp and palmoplantar psoriasis. Most patient-reported outcomes, including pruritus and the total Dermatology Life Quality Index, also improved to a significantly greater extent with apremilast than with placebo, with significant improvements in pruritus and skin discomfort/pain visual analogue scale scores seen as early as week 2 with apremilast...
February 18, 2017: Drugs
https://www.readbyqxmd.com/read/28201942/correction-to-early-clinical-response-to-tofacitinib-treatment-as-a-predictor-of-subsequent-efficacy-results-from-two-phase-3-studies-of-patients-with-moderate-to-severe-plaque-psoriasis
#4
(no author information available yet)
No abstract text is available yet for this article.
February 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28197901/safety-and-efficacy-of-brodalumab-for-moderate-to-severe-plaque-psoriasis-a-systematic-review-and-meta-analysis
#5
REVIEW
Attia Attia, Abdelrahman Ibrahim Abushouk, Hussien Ahmed, Mohamed Gadelkarim, Ahmed Elgebaly, Zeinab Hassan, Mohamed M Abdel-Daim, Ahmed Negida
BACKGROUND: Psoriasis is an inflammatory skin disease that affects 2-3% of the worldwide population. The interleukin-17 cytokine family has been proven to play a central role in the pathogenesis of psoriasis. Brodalumab is a novel biologic agent that targets interleukin-17 molecules and their receptors. We aimed to evaluate the safety and efficacy of brodalumab as a therapeutic agent for moderate-to-severe psoriasis in a meta-analysis framework. METHODS: A computer literature search of PubMed, OVID, Cochrane Central, EMBASE, EBSCO, Scopus, and Web of Science was conducted using relevant keywords...
February 14, 2017: Clinical Drug Investigation
https://www.readbyqxmd.com/read/28196317/common-skin-conditions-in-children-noninfectious-rashes
#6
Brian Z Rayala, Dean S Morrell
Cutaneous adverse drug reactions are among the most common noninfectious rashes of childhood. Cutaneous adverse drug reactions are classified as morbilliform, urticarial, bullous, pustular, or psoriasiform. Atopic dermatitis is one of the most common inflammatory cutaneous eruptions, and is characterized by pruritus and flexural distribution. Emollients and topical corticosteroids are first-line therapies. Topical calcineurin inhibitors are second-line, steroid-sparing drugs for certain conditions, such as face and eyelid eczema...
February 2017: FP Essentials
https://www.readbyqxmd.com/read/28196270/open-label-study-of-etanercept-treatment-in-patients-with-moderate-to-severe-plaque-psoriasis-who-lost-a-satisfactory-response-to-adalimumab
#7
J Bagel, S Tyring, K C Rice, D H Collier, G Kricorian, J Chung, J Iles, B S Stolshek, A Kaliyaperumal, K A Papp
BACKGROUND: Some plaque psoriasis patients experience secondary failure of tumour necrosis factor inhibitor therapy. OBJECTIVES: To evaluate efficacy, safety, and patient-reported outcomes (PROs) with etanercept in patients with secondary adalimumab failure. METHODS: This phase 4, open-label, single-arm, estimation study (NCT01543204) enrolled patients on adalimumab who had achieved static physician global assessment (sPGA) score 0/1 (clear/almost clear)...
February 14, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28194815/peristomal-psoriasis
#8
C Marshall, S Woodmansey, C C Lyon
BACKGROUND: Psoriasis is a common skin condition, affecting 1.3-2.2% of the population. The prevalence of psoriasis has previously been reported as 11.2% in patients with Crohn disease (CD) and 5.7% in patients with ulcerative colitis. AIM: To assess the prevalence of psoriasis around stoma sites and identify the most effective treatment. METHODS: A departmental database of all patients attendings stoma clinic was accessed between 1 May 2003 and 15 October 2015...
February 13, 2017: Clinical and Experimental Dermatology
https://www.readbyqxmd.com/read/28194751/juvenile-generalized-pustular-psoriasis-is-a-chronic-recalcitrant-disease-an-analysis-of-27-patients-seen-in-a-tertiary-hospital-in-johor-malaysia
#9
Bi-Wen Lau, Dee-Zhen Lim, Francesca Capon, Jonathan N Barker, Siew-Eng Choon
BACKGROUND: Limited information exists regarding juvenile generalized pustular psoriasis (GPP). We aim to determine the clinical profile and outcome of Malaysians with juvenile GPP. METHODS: Review of hospital case notes on patients with juvenile GPP. RESULTS: Twenty-seven patients with juvenile GPP were identified. Female to male ratio was 1.4:1. The median age at onset of GPP was 6.5 years. Ten patients had prior psoriasis with a median pre-pustular duration of 2...
February 14, 2017: International Journal of Dermatology
https://www.readbyqxmd.com/read/28182255/fatigue-in-psoriasis-a-controlled-study
#10
I M Skoie, I Dalen, T Ternowitz, G Jonsson, I Kvivik, K Norheim, R Omdal
BACKGROUND: Fatigue is associated with various chronic inflammatory diseases, but few studies have focused on its occurrence in psoriasis. OBJECTIVES: To describe fatigue prevalence and degree among patients with chronic plaque psoriasis compared with age- and gender-matched healthy subjects, and to examine how fatigue is influenced by essential clinical and demographic factors. METHODS: In 84 patients and 84 healthy subjects, fatigue severity was assessed using three different generic fatigue instruments: the fatigue Visual Analogue Scale (fVAS), the Fatigue Severity Scale (FSS), and the Short Form 36 (SF-36) vitality scale...
February 9, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28179246/legionella-pneumophila-pneumonia-possibly-due-to-ustekinumab-therapy-in-a-patient-with-crohn-s-disease
#11
Joaquín Borrás-Blasco, Xavier Cortes, Sergio Fernandez-Martinez, Elvira Casterá, Beatriz Antequera
PURPOSE: A case report of Legionella pneumophila pneumonia associated with off-label use of ustekinumab in a patient with Crohn's disease (CD) is presented. SUMMARY: A 57-year-old man with longstanding CD was hospitalized with a four-day history of fever (38.5 °C), dyspnea, left pleuritic pain, and weight loss (more than 6 kg) about six weeks after beginning treatment with ustekinumab, a human monoclonal antibody approved in the United States for two indications (plaque psoriasis and psoriatic arthritis) and currently under investigation as a potential treatment for CD and other inflammatory disorders...
February 15, 2017: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/28168735/does-imiquimod-pretreatment-optimize-308-nm-excimer-laser-uvb-therapy-in-psoriasis-patients
#12
Joselin D Tacastacas, Patricia Oyetakin-White, David C Soler, Andrew Young, Sarah Groft, Kord Honda, Kevin D Cooper, Thomas S McCormick
Psoriasis continues to be a debilitating skin disease affecting 1-3% of the United States population. Although the effectiveness of several current biologic therapies have described this pathology as a IL-23, TNF-α and Th17-mediated disease, less invasive approaches are still in use and in need of refinement. One of these is the usage of narrow band-UVB (NB-UVB) therapy to deplete specifically intra-epidermal CD3(+) , CD4(+) and CD8(+) cells to clear psoriatic plaques. In order to improve NB-UVB therapy, we sought to determine whether skin pre-treatment with the TLR7 agonist imiquimod (IMQ) would help increase the efficiency of the former at resolving psoriatic plaques...
February 7, 2017: Photodermatology, Photoimmunology & Photomedicine
https://www.readbyqxmd.com/read/28168661/psoriasis-in-systemic-lupus-erythematosus-a-single-center-experience
#13
Konstantinos Tselios, Kristy Su-Ying Yap, Rattapol Pakchotanon, Ari Polachek, Jiandong Su, Murray B Urowitz, Dafna D Gladman
The coexistence of psoriasis with systemic lupus erythematosus (SLE) has been reported in limited case series, raising hypotheses about shared pathogenetic mechanisms. Nevertheless, important differences regarding treatment do exist. The aim of the present study was to determine the prevalence and characteristics of psoriasis in a defined cohort of lupus patients. Patients with psoriasis were retrieved from the University of Toronto Lupus Clinic from its inception in 1970 up to 2015. Charts were hand-searched to collect information concerning demographic, clinical, and therapeutic variables...
February 6, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28162025/secukinumab-in-the-treatment-of-psoriasis-an-update
#14
Radomir Reszke, Jacek C Szepietowski
Biological drugs are pharmaceuticals manufactured using biotechnology methods that may target specific cytokines, cytokine receptors or surface molecules, and modulate the immunological response of the organism. Psoriasis is a common cutaneous disease in which biological drugs have been evaluated and widely accepted in clinical practice. Secukinumab is a monoclonal antibody targeting IL-17A which has been extensively researched in clinical trials and registered in treating moderate to severe plaque psoriasis...
February 6, 2017: Immunotherapy
https://www.readbyqxmd.com/read/28152541/alexithymia-and-plaque-psoriasis-preliminary-investigation-in-a-clinical-sample-of-250-patients
#15
Marina Talamonti, Marco Galluzzo, Stella Servoli, Simone D'Adamio, Luca Bianchi
BACKGROUND/AIMS: Psoriasis as a dermatological disorder has complex effects on mental health and the psychological status of the patient. Many authors proposed that assessing how psoriasis affects a patient's life is better than a body surface area measurement for delineating psoriasis severity. Alexithymia is a personality dimension characterized by difficulty identifying feelings, difficulty describing feelings, and externally oriented thinking observed in many clinical conditions, especially in psychosomatic disorders...
February 3, 2017: Dermatology: International Journal for Clinical and Investigative Dermatology
https://www.readbyqxmd.com/read/28150333/varicella-zoster-virus-meningitis-under-ustekinumab-because-of-plaque-psoriasis
#16
Claudia Stöllberger, Josef Finsterer
Ustekinumab, a monoclonal antibody that binds to the shared p40 subunit of interleukin (IL)-12 and IL-23, is approved in the USA and Europe for moderate to severe plaque psoriasis. There are concerns that biologic treatments like ustekinumab may lead to an increased rate of infections. We report a 77-year-old woman who developed varicella zoster virus meningitis 8 weeks after initiation of ustekinumab therapy because of plaque psoriasis. She presented clinically with sudden onset of fatigue, vertigo, nausea and epileptic seizures...
February 2, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/28147886/development-and-psychometric-evaluation-of-the-self-assessment-of-psoriasis-symptoms-saps-clinical-trial-and-the-saps-real-world-patient-reported-outcomes
#17
April W Armstrong, Benjamin Banderas, Catherine Foley, Jonathan Stokes, Murali Sundaram, Alan L Shields
OBJECTIVE: The Self-Assessment of Psoriasis Symptoms- Clinical Trials (SAPS-CT), and SAPS- Real World (SAPS-RW) were simultaneously created to assess the experience of plaque psoriasis in two unique contexts. METHODS: Qualitative and quantitative research was conducted in four phases: concept elicitation; questionnaire construction; content evaluation; and psychometric evaluation. RESULTS: Following concept elicitation, 18 concepts were selected to inform questionnaire construction of the SAPS-CT and -RW...
February 2, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28146329/dose-adjustment-of-biologic-therapies-for-psoriasis-in-dermatological-practice-a-retrospective-study
#18
M Esposito, P Gisondi, A Conti, A Giunta, M Del Giglio, M Di Mercurio, L Veneziano, G Ferrucci, L Bianchi, S Chimenti, G Girolomoni
INTRODUCTION: Despite the large routine use of biologic drugs in psoriasis treatment, the majority of studies do not take into consideration dose-adjustment practice in "real life" dermatological setting. In routine clinical practice the disease management may include a large number of conditions requiring non-standard dosage regimens, including dose-escalation, dose-reduction and/or off-label treatment interruption. OBJECTIVE: The ONDA (Outcome of non-standard dosing regimen in Psoriasis and Psoriatic Arthritis) study aim was to retrospectively analyse dose-adjustment strategies among biologic therapies for psoriasis in dermatological practice during a 3-year period...
February 1, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28138946/ixekizumab-a-review-in-moderate-to-severe-plaque-psoriasis
#19
Yahiya Y Syed
Ixekizumab (Taltz(®)) is a subcutaneously administered, humanized anti-interleukin-17A monoclonal antibody indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy (USA and EU) or phototherapy (USA). In the phase 3 UNCOVER trials in this patient population, ixekizumab was superior to placebo or etanercept in terms of the proportion of patients achieving a ≥75% reduction from baseline in the Psoriasis Area and Severity Index and in those achieving a static Physician Global Assessment score of 0 or 1, after 12 weeks of induction treatment...
February 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/28133877/efficacy-of-topical-tofacitinib-a-janus-kinase-inhibitor-in-the-treatment-of-plaque-psoriasis
#20
Nooshin Bagherani, Bruce R Smoller
No abstract text is available yet for this article.
January 30, 2017: Dermatologic Therapy
keyword
keyword
82378
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"